Lin-Xian Li
Co-Founder & Chief Executive Officer Innorna
Seminars
Wednesday 8th April 2026
Innorna: Engineering Targeted mRNA-LNPs to Advance In Vivo Immunotherapy
4:30 pm
- From Protein Replacement to In Vivo Immunotherapy: Expanding the Reach of LNPs
- Translational Insights from Preclinical and clinical
- Enabling Extrahepatic Targeting and Non-IV Delivery Across LNP Designs
NEW DATA
